Great West Life Assurance Co. Can bought a new position in Astrazeneca PLC (NYSE:AZN) during the third quarter, according to the company in its most recent filing with the SEC. The firm bought 316,751 shares of the company’s stock, valued at approximately $10,681,000.
A number of other large investors have also modified their holdings of AZN. Russell Investments Group Ltd. raised its position in Astrazeneca by 746.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 620,901 shares of the company’s stock worth $21,167,000 after purchasing an additional 547,512 shares during the period. IFP Advisors Inc raised its position in Astrazeneca by 28.5% in the 2nd quarter. IFP Advisors Inc now owns 14,570 shares of the company’s stock worth $497,000 after purchasing an additional 3,235 shares during the period. TD Asset Management Inc. raised its position in Astrazeneca by 0.6% in the 2nd quarter. TD Asset Management Inc. now owns 905,684 shares of the company’s stock worth $30,875,000 after purchasing an additional 5,421 shares during the period. Pioneer Investment Management Inc. raised its position in Astrazeneca by 1.2% in the 2nd quarter. Pioneer Investment Management Inc. now owns 1,199,570 shares of the company’s stock worth $40,894,000 after purchasing an additional 13,767 shares during the period. Finally, Trexquant Investment LP purchased a new position in Astrazeneca in the 2nd quarter worth $450,000. Institutional investors own 14.75% of the company’s stock.
A number of equities research analysts have issued reports on the stock. BNP Paribas raised shares of Astrazeneca from a “neutral” rating to an “outperform” rating in a report on Monday, September 25th. Liberum Capital lowered shares of Astrazeneca from a “buy” rating to a “hold” rating in a report on Thursday, September 14th. Investec raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. BMO Capital Markets reissued a “buy” rating and issued a $38.00 price target on shares of Astrazeneca in a report on Tuesday, November 7th. Finally, Citigroup raised shares of Astrazeneca to a “buy” rating in a report on Wednesday, October 18th. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company. Astrazeneca has an average rating of “Hold” and a consensus price target of $34.20.
Astrazeneca (NYSE:AZN) last announced its earnings results on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.55. The firm had revenue of $6.23 billion for the quarter, compared to analyst estimates of $6 billion. Astrazeneca had a net margin of 15.90% and a return on equity of 34.02%. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.32 EPS. sell-side analysts forecast that Astrazeneca PLC will post 1.87 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Great West Life Assurance Co. Can Buys New Stake in Astrazeneca PLC (AZN)” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2017/12/05/great-west-life-assurance-co-can-buys-new-stake-in-astrazeneca-plc-azn.html.
Astrazeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.